Logo Image
|Webcasts|September 26, 2019

Expanded Capabilities for Bioanalysis Leveraging a Chromatography Data System Streamline Your LC-MS Workflows

Bioanalysis is a critical tool in the drug-development process. In this webcast, discover how to increase productivity and optimize efficiency with a single-software platform for bioanalysis studies. Live: Thursday, Sept. 26, 2019, at 9am EDT | 2pm BST | 3pm CEST On demand available after final airing Sept. 26, 2020 Register free

Register free: http://www.chromatographyonline.com/lcgc_w/data_system

Event Overview:
Bioanalytical studies performed with LC-MS are a fundamental part of the drug-development process; continually evolving regulatory guidelines and intensified demands on data integrity mean that traceability, accuracy, and integrity of any associated data is vital to ensure the safety of therapeutic products.

In this webcast, you will learn how seamless integration of chromatography, mass spectrometry (both Quadrupole and High Resolution), chromatography data system (CDS) software and your laboratory information management system (LIMS) create a compliant, secure, scalable, and reliable solution for bioanalysis studies whilst increasing laboratory efficiency and throughput.

Key Learning Objectives:

  • Find out how a software workflow designed to meet the needs of bioanalysis can streamline your processes

  • Learn how a CDS can expand the potential for quadrupole and high-resolution mass spectrometry within your laboratory

  • Discover how the use of a single-software platform can increase productivity and optimize efficiency using compliance tools, networking capabilities, data processing, and more

Speaker: Peter Zipfell, Product Marketing Specialist, Thermo Fisher Scientific

Time and Date: Thursday, Sept. 26, 2019, at 9am EDT | 2pm BST | 3pm CEST

On demand available after final airing Sept. 26, 2020

Sponsor: Thermo Fisher Scientific

Register free: http://www.chromatographyonline.com/lcgc_w/data_system

Related to this article

View more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more